These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2203303)

  • 21. Treatment of urinary tract infections: selecting an appropriate broad-spectrum antibiotic for nosocomial infections.
    Sharifi R; Geckler R; Childs S
    Am J Med; 1996 Jun; 100(6A):76S-82S. PubMed ID: 8678101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.
    Merdjan H; Rangaraju M; Tarral A
    Clin Drug Investig; 2015 May; 35(5):307-17. PubMed ID: 25813217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of cefepime and comparison with those of ceftiofur in horses.
    Guglick MA; MacAllister CG; Clarke CR; Pollet R; Hague C; Clarke JM
    Am J Vet Res; 1998 Apr; 59(4):458-63. PubMed ID: 9563631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of age and gender on pharmacokinetics of cefepime.
    Barbhaiya RH; Knupp CA; Pittman KA
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1181-5. PubMed ID: 1416818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous administration of cefepime.
    Walker P; Neuhauser MN; Tam VH; Willey JS; Palmer JL; Bruera E; Prince RA
    J Pain Symptom Manage; 2005 Aug; 30(2):170-4. PubMed ID: 16125032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
    Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
    Br J Clin Pharmacol; 2000 Aug; 50(2):184-91. PubMed ID: 10930972
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.
    Reed MD; Yamashita TS; Knupp CK; Veazey JM; Blumer JL
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1783-7. PubMed ID: 9257761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of multiple-dose cefprozil and comparison with cefaclor.
    Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1198-203. PubMed ID: 2393281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.
    Allaouchiche B; Breilh D; Jaumain H; Gaillard B; Renard S; Saux MC
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2424-7. PubMed ID: 9371344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units.
    Baririan N; Chanteux H; Viaene E; Servais H; Tulkens PM
    J Antimicrob Chemother; 2003 Mar; 51(3):651-8. PubMed ID: 12615867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid.
    Kalman D; Barriere SL; Johnson BL
    Antimicrob Agents Chemother; 1992 Feb; 36(2):453-7. PubMed ID: 1605609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of cefepime pharmacokinetics in neonatal foals and adult dogs.
    Gardner SY; Papich MG
    J Vet Pharmacol Ther; 2001 Jun; 24(3):187-92. PubMed ID: 11442796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.
    Ge Y; Whitehouse MJ; Friedland I; Talbot GH
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3427-31. PubMed ID: 20457817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetic profile of a new generation of parenteral cephalosporin.
    Rybak M
    Am J Med; 1996 Jun; 100(6A):39S-44S. PubMed ID: 8678096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of single-dose BMY-28100, a new oral cephalosporin.
    Barbhaiya RH; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA
    Antimicrob Agents Chemother; 1990 Feb; 34(2):202-5. PubMed ID: 2327766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefepime pharmacokinetics in cystic fibrosis.
    Hamelin BA; Moore N; Knupp CA; Ruel M; Vallée F; LeBel M
    Pharmacotherapy; 1993; 13(5):465-70. PubMed ID: 8247913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefepime versus cefpirome: the importance of creatinine clearance.
    Lipman J; Wallis SC; Boots RJ
    Anesth Analg; 2003 Oct; 97(4):1149-1154. PubMed ID: 14500173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.
    Holloway WJ; Palmer D
    Am J Med; 1996 Jun; 100(6A):52S-59S. PubMed ID: 8678098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.
    McKinnon PS; Paladino JA; Schentag JJ
    Int J Antimicrob Agents; 2008 Apr; 31(4):345-51. PubMed ID: 18313273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.